Latest Breaking News On - American society for hematology annual meeting - Page 1 : comparemela.com

Sangamo Therapeutics Reports Recent Business Highlights and Fourth Quarter and Full Year 2023 Financial Results

Data from novel proprietary neurotropic adeno-associated virus delivery capsid, STAC-BBB, demonstrated industry-leading blood-brain barrier penetration in non-human primates following intravenous.

United statesProvence alpes côd azurSan diegoSandy macraeRegulatory agencyCapsid delivery technologyCompany frenchAmerican society for hematology annual meetingSangamo therapeutics incExchange commissionAldrich corporationSangamo therapeuticsChief executive officerDelivery technologyNeuropathic painEnzyme replacement therapy

Sangamo Therapeutics Announces Strategic Update and Reports Third Quarter 2023 Financial Results

01.11.2023 - Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicines company, today announced recent business highlights, including progress on its strategic transformation and a corresponding restructuring of operations and workforce reduction, and .

United statesLang schwarzGregory davisD mark mcclungJason fontenotKamy poolerSafety monitoring committeeAmerican society for hematology annual meetingExchange commissionHead of researchHead of technologyEuropean society of geneExecutive vice presidentChief operating officerSenior vice presidentChief scientific officer

Salarius Pharmaceuticals (SLRX) Reports No Adverse Safety Signals from Two Toxicology Studies of SP-3164

Salarius Pharmaceuticals (SLRX) Reports No Adverse Safety Signals from Two Toxicology Studies of SP-3164
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesRelationskim sutton golodetzDavid arthurExchange commissionDrug administrationSalarius pharmaceuticals incResearch institute of texasGood laboratory practiceAmerican association for cancer research annual meetingProduct development awardNational pediatric cancer foundationAmerican society for hematology annual meetingMd anderson cancer centerSalarius pharmaceuticalssalarius pharmaceuticals incInvestigational new drugHodgkin lymphomas

FCS Clinical Trials Lead to FDA Approval of New Targeted Drug for Patients with Mantle Cell Lymphoma

/PRNewswire/ The FDA has approved the first Non-Covalent (Reversible) BTK (Bruton Tyrosine Kinase) inhibitor for the treatment of Relapsed or Refractory.

United statesGustavoa fonsecaColleen lewisPirtobrutinib jaypircaDrug development unit in sarasotaAmerican society of clinical oncologyDrug development manish patelAmerican society for hematology annual meetingNursing researchClinical researchFlorida cancer specialists research instituteDrug development unitsBruton tyrosine kinaseRefractory mantle cell lymphomaFlorida cancer specialistsDevelopment unit

Gene therapy sustains bleeding control in haemophilia A trial

Gene therapy sustains bleeding control in haemophilia A trial
europeanpharmaceuticalreview.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from europeanpharmaceuticalreview.com Daily Mail and Mail on Sunday newspapers.

United statesTseng chengRob schottEuropean medicines agencyHead of development at sangamoDrug administrationAmerican society for hematology annual meetingSangamo therapeuticsAmerican societyHematology annual meetingSenior vice presidentChief scientific officerPfizer rareOrphan drugFast trackOrphan medicinal product